Carbamazepine Labeling To Advise Genetic Screen To Avoid Side Effect
Executive Summary
Labeling for carbamazepine drugs will be revised to recommend patients of Asian descent be genetically screened prior to starting therapy to help identify those at an increased risk of a serious side effect, FDA announced Dec. 12
You may also be interested in...
Warfarin Label Change Falls Short of Recommending Genetic Testing
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.